Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.52 |
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28359890 | 1.00 | GPR84 (0.52) | GPR84NAAAFFAR1ACHELMNA | |
| SCHEMBL12802821 | 1.00 | GPR84 (0.52) | GPR84NAAAFFAR1ACHELMNA | |
| SCHEMBL3804227 | 1.00 | GPR84 (0.52) | GPR84NAAAFFAR1ACHELMNA | |
| SCHEMBL5692272 | 1.00 | GPR84 (0.52) | GPR84NAAAFFAR1ACHELMNA | |
| SCHEMBL16275126 | 1.00 | GPR84 (0.52) | GPR84NAAAFFAR1ACHELMNA | |
| SCHEMBL8714299 | 1.00 | GPR84 (0.52) | GPR84NAAAFFAR1ACHELMNA | |
| Pentane SCHEMBL8332570 | 0.98 | GPR84 (0.50) | GPR84NAAAFFAR1ACHELMNA | |
| SCHEMBL27844490 | 0.93 | ACHE (0.49) | GPR84NAAAFFAR1ACHEALDH1A1 | |
| SCHEMBL8573341 | 0.93 | GPR84 (0.46) | GPR84NAAAFFAR1ACHELMNA | |
| Alcohol SCHEMBL29140150 | 0.93 | GPR84 (0.55) | GPR84NAAAFFAR1TSHREPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 675 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4604746-B1 | ORAL PRODUCT COMPRISING THEOBROMINE | CONTRAF NICOTEX TOBACCO GMBH (DE) | 2026-05-13 | — | — | EP | claimed |
| EP-4523549-A1 | ORAL PRODUCT COMPRISING THEOBROMINE | Contraf-Nicotex-Tobacco GmbH (DE) | 2025-03-19 | — | — | EP | claimed |
| US-20250000770-A1 | ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING KETYL/ACETYL OF GLYCERIN COMPOUND | L'OREAL (FR) | 2025-01-02 | — | — | US | claimed |
| US-20210186887-A1 | MOISTURE RESISTANT PROBIOTIC GRANULE AND METHODS OF PRODUCING THE SAME | POLYCAPS HOLDINGS LTD (IL) | 2021-06-24 | — | — | US | claimed |
| EP-2863996-B1 | LIQUID COSMETIC COMPOSITION COMPRISING AN OIL, HYDROPHOBIC SILICA AEROGEL PARTICLES AND A WAX WITH A MELTING POINT OF GREATER THAN 60°C | OREAL (FR) | 2021-03-24 | — | — | EP | claimed |
| EP-3781137-A1 | MOISTURE RESISTANT PROBIOTIC GRANULE AND METHODS OF PRODUCING THE SAME | Polycaps Holdings Ltd. (IL) | 2021-02-24 | — | — | EP | claimed |
| US-20200405797-A1 | TRANSMUCOSAL DELIVERY DEVICE AND METHOD OF MANUFACTURING SAME | NANOSTRIPS, INC. (US) | 2020-12-31 | — | — | US | claimed |
| US-20200093717-A1 | EXFOLIATING AND HYDRATING MAKEUP REMOVING COMPOSITIONS | L'OREAL (FR) | 2020-03-26 | — | — | US | claimed |
| US-10576031-B1 | Exfoliating and hydrating makeup removing compositions | L'OREAL (FR) | 2020-03-03 | — | — | US | claimed |
| US-10543175-B1 | Film composition and methods for producing the same | DEGAMA BERRIER LTD (KY) | 2020-01-28 | — | — | US | claimed |
| US-8663692-B1 | Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same | PHARMASOL GMBH (DE) | 2014-03-04 | — | — | US | claimed |
| WO-2013190129-A1 | LIQUID COSMETIC COMPOSITION COMPRISING AN OIL, HYDROPHOBIC SILICA AEROGEL PARTICLES AND A WAX WITH A MELTING POINT OF GREATER THAN 60°C | L'OREAL (FR) | 2013-12-27 | — | — | WO | claimed |
| EP-2549977-A2 | LIPID NANOPARTICLE CAPSULES | Lipotec, S.A. (ES) | 2013-01-30 | — | — | EP | claimed |
| US-20130017239-A1 | LIPID NANOPARTICLE CAPSULES | LIPOTEC S.A. (ES) | 2013-01-17 | — | — | US | claimed |
| WO-2012168882-A1 | COMPOSITIONS AND METHODS FOR IMPROVING STABILITY AND EXTENDING SHELF LIFE OF SENSITIVE FOOD ADDITIVES AND FOOD PRODUCTS THEREOF | SPAI Group Ltd. (US) | 2012-12-13 | — | — | WO | claimed |
| WO-2011116963-A2 | LIPID NANOPARTICLE CAPSULES | LIPOTEC S.A. (ES) | 2011-09-29 | — | — | WO | claimed |
| US-20090142289-A1 | COMPOSITION CONTAINING A HARD WAX AND A PASTY COMPOUND, AND PROCESS FOR THE CARE OR MAKING UP OF THE EYELASHES | L'OREAL (FR) | 2009-06-04 | — | — | US | claimed |
| US-20050053636-A1 | Cosmetic and dermatological care oils containing waxes | BEIERSDORF AG (DE) | 2005-03-10 | — | — | US | claimed |
| EP-0680746-B1 | Sunscreen composition | SPIRIG PHARMA AG (CH) | 2001-10-24 | — | — | EP | claimed |
| EP-0580620-B1 | STABLE MULTIPLE EMULSIONS | BEIERSDORF AG (DE) | 2000-10-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093717-A1 | EXFOLIATING AND HYDRATING MAKEUP REMOVING COMPOSITIONS | DSG1, AQP3, AQP1 | GPR84 3087/4885NAAA 808/4885FFAR1 520/4885 |
| US-20250000770-A1 | ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING KETYL/ACETYL OF GLYCERIN COMPOUND | GK, KAT8, KAT5 | GPR84 661/4885NAAA 513/4885FFAR1 768/4885 |
| US-10543175-B1 | Film composition and methods for producing the same | LCAT, LCT, LIPA | GPR84 1705/4885NAAA 1119/4885FFAR1 612/4885 |
| US-10576031-B1 | Exfoliating and hydrating makeup removing compositions | DSG1, AQP3, AQP1 | GPR84 3087/4885NAAA 808/4885FFAR1 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.